Table 1:
Tocilizumab eligibility among patients admitted to hospital with COVID-19 between Jan. 1 and June 30, 2020, at 6 hospitals in Toronto and Mississauga, Ontario
| Characteristic | No. (%) of patients admitted to hospital with COVID-19* | |||||
|---|---|---|---|---|---|---|
| Overall | Aged < 50 yr | Aged 50–59 yr | Aged 60–69 yr | Aged 70–79 yr | Aged > 79 yr | |
| No. of hospital admissions | 820 | 155 (18.9) | 126 (15.4) | 157 (19.1) | 164 (20.0) | 218 (26.6) |
| Age, yr; median (IQR) | 68 (54–80) | 40 (32–45) | 55 (53–57.75) | 64 (62–67) | 74 (72–77) | 86 (82–90) |
| Sex, female | 343 (41.8) | 53 (34.2) | 51 (40.5) | 56 (35.7) | 59 (36.0) | 124 (56.9) |
| No. of ICU admissions | 153 (18.7) | 25 (16.1) | 35 (27.8) | 41 (26.1) | 38 (23.2) | 14 (6.4) |
| Patients who died in hospital | 167 (20.4) | ≤ 5 (≤ 3.2)§ | 9 (7.1) | 20 (12.7) | 37 (22.6) | 98 (45.0) |
| Patients who met the CRP criterion/CRP measured† | 216 (50.8) n = 425 |
40/91 (44.0) | 41/73 (56.2) | 35/78 (44.9) | 46/83 (55.4) | 54/100 (54.0) |
| Patients who met oxygenation criterion‡ | 493 (60.1) | 58 (37.4) | 79 (62.7) | 87 (55.4) | 108 (65.9) | 161 (73.9) |
| Patients who were eligible for the tocilizumab RECOVERY trial primary estimate | 348 (42.4) | 42 (27.1) | 59 (46.8) | 68 (43.3) | 81 (49.4) | 98 (45.0) |
| Patients who were eligible for the tocilizumab RECOVERY trial lower bound estimate | 262 (32.0) | 33 (21.3) | 54 (42.9) | 53 (33.8) | 64 (39.0) | 58 (26.6) |
| Patients who were eligible for the tocilizumab RECOVERY trial upper bound estimate | 411 (50.1) | 44 (28.4) | 68 (54.0) | 75 (47.8) | 94 (57.3) | 130 (59.6) |
| Patients who were eligible for the tocilizumab RECOVERY trial complete data | 200 (47.1) n = 425 |
25/91 (27.5) | 40/73 (54.8) | 35/78 (44.9) | 49/83 (59.0) | 51/100 (51.0) |
| Patients who were eligible for the tocilizumab REMAP-CAP trial | 268 (32.7) | 31 (20.0) | 44 (34.9) | 54 (34.4) | 61 (37.2) | 78 (35.8) |
Note: CRP = C-reactive protein, ICU = intensive care unit, IQR = interquartile range, RECOVERY = Randomised Evaluation of COVID-19 Therapy, REMAP-CAP = Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia.
Unless stated otherwise.
CRP level ≥ 75 mg/L at any point during their hospital stay.
Oxygen saturation on room air was < 92%, required oxygen therapy or intensive care. To provide a lower and upper bound on the tocilizumab eligibility estimate, we imputed all missing CRP results as < 75 and ≥ 75 mg/L, respectively.
Exact number suppressed to reduce risk of patient reidentification.